Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study Journal Article


Authors: Nooka, A. K.; Kaufman, J. L.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y.; Reeves, B.; Wildes, T. M.; Holstein, S. A.; Anderson, L. D. Jr; Badros, A.; Shune, L.; Chari, A.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T. S.; Voorhees, P. M.; Usmani, S. Z.; Richardson, P. G.
Article Title: Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
Abstract: Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients. © 2024 Janssen Scientific Affairs, LLC. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Keywords: adult; controlled study; aged; middle aged; overall survival; lenalidomide; clinical trial; constipation; fatigue; neutropenia; diarrhea; drug efficacy; drug safety; follow up; antineoplastic agent; progression free survival; bortezomib; multiple myeloma; anemia; leukopenia; nausea; neuropathy; randomized controlled trial; thrombocytopenia; vomiting; antineoplastic combined chemotherapy protocols; obesity; dexamethasone; monoclonal antibody; arthralgia; coughing; pneumonia; rash; antibodies, monoclonal; body mass; minimal residual disease; multicenter study; diabetes mellitus; peripheral edema; headache; drug therapy; racial disparity; ethnicity; african american; clinical trials; caucasian; upper respiratory tract infection; race; post hoc analysis; asian; complete remission; antibody therapy; humans; human; male; female; article; black person; daratumumab; black or african american; haematological malignancy
Journal Title: British Journal of Haematology
Volume: 204
Issue: 6
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2024-06-01
Start Page: 2227
End Page: 2232
Language: English
DOI: 10.1111/bjh.19386
PUBMED: 38504552
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Saad Zafar Usmani
    312 Usmani